Y-mabs Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Y-mAbs Therapeutics Director Laura Hamill reported the disposition of common stock, restricted stock units, and stock options following the company's acquisition by Stark International Lux.
WG Biotech ApS reports the disposition of all its Y-mAbs Therapeutics shares following the company's merger into a private entity at $8.60 per share.
Y-mAbs Therapeutics SVP Douglas J. Gentilcore's stock options were converted to cash following the company's merger on September 16, 2025.
Director David N. Gill's Y-mAbs Therapeutics holdings were converted to cash following the company's acquisition by Stark International Lux.
Y-mAbs Therapeutics Director Ashu Tyagi reported the disposition of common stock and cancellation of restricted stock units and stock options following the company's acquisition.
Y-mAbs Therapeutics Chief Business Officer Thomas Gad disposed of all his common stock, RSUs, PRSUs, and stock options following the company's acquisition by Perseus BidCo US, Inc. for $8.60 per share.
Y-mAbs Therapeutics' EVP, CFO, and Treasurer, Peter P. Pfreundschuh, converted all his equity holdings into cash following the company's merger.
Y-mAbs Therapeutics President & CEO Michael J. Rossi reported the disposition of common stock and conversion of equity awards following the company's acquisition by Stark International Lux.
Y-mAbs Therapeutics' SVP & COO, Joris Wilms, disposed of common stock and had equity awards converted to cash following the company's merger on September 16, 2025.
Y-mAbs Therapeutics, Inc. has completed its merger, becoming an indirect wholly-owned subsidiary of Stark International Lux, with shareholders receiving $8.60 per share in cash.
Y-mAbs Therapeutics SVP John LaRocca converted restricted stock units and stock options into cash following the company's merger with Yosemite Merger Sub, Inc.
Y-mAbs Therapeutics, Inc. completed its merger, becoming an indirect wholly-owned subsidiary of Perseus BidCo US, Inc., with shareholders receiving $8.60 per share in cash.
Y-mAbs Therapeutics, Inc. Director Laura Hamill was granted 25,080 restricted stock units and 33,450 stock options, aligning her interests with shareholders.
Y-mAbs Therapeutics, Inc. Director Ashu Tyagi has increased beneficial ownership through the acquisition of 25,080 Restricted Stock Units and 33,450 employee stock options, aligning interests with shareholders.
A director and 10% owner of Y-mAbs Therapeutics, Inc. reported the acquisition of restricted stock units and employee stock options, alongside a disposal of common stock, as part of compensation.
Y-mAbs Therapeutics, Inc. Director James Healy was granted 25,080 restricted stock units and 33,450 employee stock options, signaling continued alignment with company performance.
Y-mAbs Therapeutics, Inc. Director David N. Gill was granted 25,080 restricted stock units and 33,450 employee stock options on June 30, 2025, as part of the company's 2018 Equity Incentive Plan.
Form 4: Y-mAbs Therapeutics Chief Business Officer Exercises Stock Options, Boosts Direct Shareholding
Thomas Gad, Chief Business Officer and Director of Y-mAbs Therapeutics, Inc., exercised employee stock options to acquire 103,000 shares of common stock at $2 per share, significantly increasing his direct beneficial ownership.
Michael J. Rossi, President and CEO of Y-mAbs Therapeutics, sold 3,917 shares of common stock on March 7, 2025, to cover tax liabilities associated with vesting restricted stock units.
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold 10,810 shares of common stock to cover tax liabilities associated with vesting restricted stock units.
Form 4: Y-mAbs Therapeutics CFO Peter Pfreundschuh Receives Stock Options and Restricted Stock Units
Y-mAbs Therapeutics CFO and Treasurer, Peter Pfreundschuh, was granted stock options and restricted stock units as part of the company's 2018 Equity Incentive Plan.
Y-mAbs Therapeutics Chief Business Officer Thomas Gad received stock and option grants, increasing his beneficial ownership in the company.
Douglas J. Gentilcore, SVP and Danyelza Business Unit Head at Y-mAbs Therapeutics, was granted 142,600 stock options on January 17, 2025.
SVP and Chief Operating Officer of Y-mAbs Therapeutics, Joris Wilms, reports the acquisition of restricted stock units and stock options.
Y-mAbs Therapeutics CEO Michael Rossi was granted 210,700 stock options and 105,300 restricted stock units on January 17, 2025, according to a recent SEC filing.
John LaRocca, SVP, General Counsel & Secretary of Y-mAbs Therapeutics, was granted stock options and restricted stock units as part of the company's 2018 Equity Incentive Plan.
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, exercised stock options to acquire 22,831 shares of common stock.
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold a total of 95,000 shares of common stock in two transactions on September 13 and 16, 2024.
Torben Lund-Hansen, SVP & Chief Technical Officer of Y-mAbs Therapeutics, exercised stock options and sold 50,000 shares of common stock on August 28, 2024.
Joris Wilms, SVP & Chief Operating Officer of Y-mAbs Therapeutics, sold 5,000 shares of common stock on August 26, 2024, at a price of $14.69 per share.